The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lindhofer, H.
Right arrow Articles by Thierfelder, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindhofer, H.
Right arrow Articles by Thierfelder, S.

The Journal of Immunology, Vol 155, Issue 1 219-225, Copyright © 1995 by American Association of Immunologists

ARTICLES

Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies

H Lindhofer, R Mocikat, B Steipe and S Thierfelder
GSF, Immunology Institute, Munich, Germany.

Conventional mouse/mouse or rat/rat hybrid-hybridoma supernatants contain up to 10 different IgG molecules consisting of various combinations of heavy and light chains. Hence, the yield of functional bispecific Ab is low, and purification is often complicated, hampering a general preclinical evaluation of, e.g., bispecific Ab-mediated tumor immunotherapy in animal models. In experiments to overcome this drawback we found that fusion of rat with mouse hybridomas opens the possibility of large scale production of bispecific Ab due to the increased incidence of correctly paired Ab and facilitated purification. In essence, rat/mouse quadroma-derived bispecific Ab have the following advantages: 1) enrichment of functional bispecific Ab because of preferential species-restricted heavy/light chain pairing (observed in four of four rat-mouse quadromas) in contrast to the random pairing in conventional mouse/mouse or rat/rat quadromas, and 2) a possible one-step purification of the quadroma supernatant with protein A. This simple chromatography step does not bind unwanted variants with parental rat/rat heavy chain configuration, and the desired rat/mouse bispecific Ab are retained, which can then easily be separated from parental mouse Ab by sequential pH elution.


This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
F. Hirschhaeuser, T. Leidig, B. Rodday, C. Lindemann, and W. Mueller-Klieser
Test System for Trifunctional Antibodies in 3D MCTS Culture
J Biomol Screen, September 1, 2009; 14(8): 980 - 990.
[Abstract] [PDF]

Home page
 J BiochemHome page
A. Natsume, M. Wakitani, N. Yamane-Ohnuki, E. Shoji-Hosaka, R. Niwa, K. Uchida, M. Satoh, and K. Shitara
Fucose Removal from Complex-Type Oligosaccharide Enhances the Antibody-Dependent Cellular Cytotoxicity of Single-Gene-Encoded Bispecific Antibody Comprising of Two Single-Chain Antibodies Linked to the Antibody Constant Region
J. Biochem., September 1, 2006; 140(3): 359 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Kiewe, S. Hasmuller, S. Kahlert, M. Heinrigs, B. Rack, A. Marme, A. Korfel, M. Jager, H. Lindhofer, H. Sommer, et al.
Phase I Trial of the Trifunctional Anti-HER2 x Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer.
Clin. Cancer Res., May 15, 2006; 12(10): 3085 - 3091.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Morecki, H. Lindhofer, E. Yacovlev, Y. Gelfand, and S. Slavin
Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes
Blood, February 15, 2006; 107(4): 1564 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Avin, J. Haimovich, and N. Hollander
Anti-Idiotype x Anti-CD44 Bispecific Antibodies Inhibit Invasion of Lymphoid Organs by B Cell Lymphoma
J. Immunol., October 1, 2004; 173(7): 4736 - 4743.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Kronenberger, A. Dieckmann, M. Selmayr, J. Strehl, U. Wahl, H. Lindhofer, G. Kraal, and R. Mocikat
Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells
Blood, February 15, 2002; 99(4): 1327 - 1331.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Ruf and H. Lindhofer
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Blood, October 15, 2001; 98(8): 2526 - 2534.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
R. Riesenberg, A. Buchner, H. Pohla, and H. Lindhofer
Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies ({{alpha}}EpCAM {{alpha}}CD3)
J. Histochem. Cytochem., July 1, 2001; 49(7): 911 - 918.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Zeidler, G. Reisbach, B. Wollenberg, S. Lang, S. Chaubal, B. Schmitt, and H. Lindhofer
Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing
J. Immunol., August 1, 1999; 163(3): 1246 - 1252.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.